Incontinence (Treatment)

New Formulation of Anti-Incontinence Drug Marketed in Finland

Published in Women's Health Weekly, May 18th, 1998

Penwest Pharmaceuticals Co., a wholly-owned subsidiary of Penford Corporation, announced the availability in its first market, Finland, of Cystrin CR^R (oxybutynin, 10 mg), the first commercially available drug to incorporate the Timerx^R controlled release delivery system.

"This is an advancement for people who suffer from urinary incontinence because current therapies on the market require administration two to four times a day," said Jack V. Talley, Penwest Pharmaceuticals Co. "The once-daily dosing schedule of controlled release oxybutynin makes it more convenient to administer, especially for patients who suffer during the night."

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1998-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry